Expert consensus on clinical management strategies for infections caused by extended-spectrum β-lactamase-producing Enterobacterales(2025)
10.12138/j.issn.1671-9638.20252562
- VernacularTitle:临床产超广谱β-内酰胺酶肠杆菌目细菌感染应对策略专家共识(2025)
- Author:
Chao ZHUO
1
;
Yingchun XU
;
Yunsong YU
Author Information
1. 广州医科大学附属第一医院感染科
- Publication Type:Journal Article
- Keywords:
extended-spectrum β-lactamase;
ESBL-producing Enterobacterales;
antimicrobial agent;
targeted therapy;
stratified treatment;
consensus
- From:
Chinese Journal of Infection Control
2025;24(9):1191-1207
- CountryChina
- Language:Chinese
-
Abstract:
Enterobacterales are important pathogens responsible for healthcare-associated infections and can cause various severe infectious diseases.Since their first report,extended-spectrum β-lactamase-producing Enterobactera-les(ESBL-E)have become widely prevalent worldwide.These strains often exhibit multidrug resistance,signifi-cantly increase the risk of treatment failure and patient mortality.In China,the prevention and control of ESBL-E faces numerous challenges,including high prevalence rates,significant regional distribution disparities,uneven la-boratory detection capabilities,and variations in antimicrobial stewardship and prescribing practices.To address these issues,Professors Zhuo Chao,Xu Yingchun and Yu Yunsong initiated the development of the Expert consen-sus on clinical management strategies for infections caused by extended-spectrum β-lactamase-producing Ente-robacterales(2025),in collaboration with multidisciplinary experts.This consensus systematically reviews the global and domestic epidemiological characteristics of ESBL-E,clinical laboratory detection techniques,treatment principles and key therapeutic agents,as well as infection prevention and control measures.Furthermore,it elabo-rates on the microbiological features and stratified treatment strategies for infections of different sources(including bloodstream,intracranial,respiratory system,thoracic mediastinal,intra-abdominal,and urinary tract infections)and special populations(such as neutropenic patients with fever,emergency patients,and pediatric patients).The consensus aims to enhance the detection capacity of clinical laboratories for ESBL-E,standardize diagnosis and treat-ment strategies in healthcare settings,and provide scientific guidance to curb the spread of ESBL-E in China,there-by reducing associated morbidity and mortality.
